Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

Abstract Background There is limited evidence in the literature on the long-term effectiveness and cost-effectiveness of treatments for Acute Severe Ulcerative Colitis (ASUC). The study aimed to perform decision analytic model-based long-term cost-utility analysis (CUA) of infliximab versus ciclospo...

Full description

Bibliographic Details
Main Authors: Mohammed Fasihul Alam, Mirella Longo, David Cohen, Sam Groves, Laith Alrubaiy, Hayley A. Hutchings, Alan Watkins, Shaji Sebastain, John G. Williams
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Health Services Research
Subjects:
Ulcerative colitis
Infliximab
Ciclosporin
Cost-effectiveness
Decision tree
Markov model
Online Access:https://doi.org/10.1186/s12913-023-09233-w

Internet

https://doi.org/10.1186/s12913-023-09233-w

Similar Items